

<b>SUPPLEMENTAL LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>					ATTY. DOCKET NO. <b>8449-128-999</b>		APPLICATION NO. <b>09/668,724</b>	
					APPLICANT <b>Srivastava, Pramod K.</b>			
					FILING DATE <b>September 22, 2000</b>		GROUP <b>1642</b>	

  

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

  

FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
					YES	NO	
<b>CY</b>	<b>DN</b>	<b>WO 00/54801</b>	<b>09/21/00</b>	<b>PCT</b>			
<b>CY</b>	<b>DO</b>	<b>WO 02/07755</b>	<b>1/3/2002</b>	<b>PCT</b>			
<b>CY</b>	<b>DP</b>	<b>WO 94/14471</b>	<b>07/07/1994</b>	<b>PCT</b>			

  

OTHER REFERENCES <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
<b>CY</b>	<b>DQ</b>	Agostoni et al., 1994, "Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator." <i>Circulation</i> . 90(6):2666-70.
<b>CY</b>	<b>DR</b>	Bednar et al., 1997, "Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke." <i>J. Neurosurg.</i> 86(1):139-42.
<b>CY</b>	<b>DS</b>	Collen et al., 1989, "Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent." <i>Drugs</i> . 38(3):346-88.
<b>CY</b>	<b>DT</b>	Katsutani et al., 1992, "Immunogenic properties of structurally modified human tissue plasminogen activators in chimpanzees and mice." <i>Fundam Appl Toxicol.</i> 19(4):555-62.
<b>CY</b>	<b>DU</b>	Opekun et al., 1999, "Novel therapies for Helicobacter pylori infection." <i>Aliment Pharmacol Ther.</i> 13(1):35-41.
<b>CY</b>	<b>DV</b>	Reed et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." <i>Thromb Haemost.</i> 64(2):276-80.
<b>CY</b>	<b>DW</b>	Zimecki et al., 1999, "Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells." <i>Arch Immunol Ther Exp (Warsz).</i> 47(2):113-8.

  

EXAMINER <b>Chung H HX</b>	DATE CONSIDERED <b>2-20-03</b>
----------------------------	--------------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conference and not considered. Include copy of this form with next communication to applicant.